{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+Tumors", "query": { "condition": "Kidney Tumors" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1780, "total_pages": 178, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+Tumors&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T20:26:30.422Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00471536", "title": "Pazopanib in Treating Patients With Metastatic Urothelial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Distal Urethral Cancer", "Proximal Urethral Cancer", "Recurrent Bladder Cancer", "Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter", "Recurrent Urethral Cancer", "Stage IV Bladder Cancer", "Transitional Cell Carcinoma of the Bladder", "Urethral Cancer Associated With Invasive Bladder Cancer" ], "interventions": [ { "name": "pazopanib hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2008-08", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2014-05-30", "last_synced_at": "2026-07-23T20:26:30.422Z", "location_count": 7, "location_summary": "Jacksonville, Florida • Baltimore, Maryland • Detroit, Michigan + 4 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Saint Louis Park", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00471536" }, { "nct_id": "NCT00459875", "title": "Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "sunitinib malate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 24, "start_date": "2007-03", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2015-11-26", "last_synced_at": "2026-07-23T20:26:30.422Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00459875" }, { "nct_id": "NCT05520099", "title": "Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform (ELEPHAS-02)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Immunotherapy", "Cancer", "Bladder Cancer", "Urothelial Carcinoma Bladder", "Kidney Cancer", "Clear Cell Renal Cell Cancer (ccRCC)", "Colorectal Cancer", "MSI-H Colorectal Cancer", "DMMR Colorectal Cancer", "Head and Neck Cancer (H&N)", "Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)", "Liver Cancer", "Hepatocellular Carcinoma (HCC)", "Lung Cancer (NSCLC)", "NSCLC (Non-small Cell Lung Cancer)", "Skin Cancer", "Cutaneous Melanoma", "Endometrial Cancer", "Solid Tumor Cancer" ], "interventions": [ { "name": "Core Needle Biopsy, Forceps Biopsy, Punch Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Elephas", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 416, "start_date": "2023-06-26", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-07-23T20:26:30.422Z", "location_count": 12, "location_summary": "Little Rock, Arkansas • Salinas, California • Orlando, Florida + 9 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Salinas", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Pembroke Pines", "state": "Florida" }, { "city": "Stuart", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05520099" }, { "nct_id": "NCT01183663", "title": "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2010-08", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-07-23T20:26:30.422Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183663" }, { "nct_id": "NCT01999972", "title": "A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "axitinib", "type": "DRUG" }, { "name": "crizotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2014-02-26", "completion_date": "2019-09-05", "has_results": true, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-07-23T20:26:30.422Z", "location_count": 15, "location_summary": "Chicago, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 5 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01999972" }, { "nct_id": "NCT00101972", "title": "RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "monoclonal antibody RAV12", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2004-12", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2022-02-22", "last_synced_at": "2026-07-23T20:26:30.422Z", "location_count": 5, "location_summary": "Santa Monica, California • Washington D.C., District of Columbia • Miami, Florida + 2 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00101972" }, { "nct_id": "NCT05410509", "title": "\"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)\"", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Renal Cell Carcinoma (RCC)" ], "interventions": [ { "name": "Trans-arterial embolization (TAE)", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2024-01-03", "completion_date": "2025-11-19", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-07-23T20:26:30.422Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Stanford, California • Rochester, Minnesota + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Stanford", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05410509" }, { "nct_id": "NCT00096629", "title": "Vaccine Therapy in Treating Patients With Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "human prostate-specific membrane antigen plasmid DNA vaccine", "type": "BIOLOGICAL" }, { "name": "mouse prostate-specific membrane antigen plasmid DNA vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2003-11", "completion_date": "2018-04", "has_results": false, "last_update_posted_date": "2018-04-25", "last_synced_at": "2026-07-23T20:26:30.422Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096629" }, { "nct_id": "NCT00458536", "title": "Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Renal Cancer" ], "interventions": [ { "name": "Dendritic Cell Tumor Fusion Vaccine", "type": "BIOLOGICAL" }, { "name": "Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2004-10", "completion_date": "2023-07", "has_results": true, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-07-23T20:26:30.422Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00458536" }, { "nct_id": "NCT05001009", "title": "Goals of Care Conversations Study", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Seriously Ill Patients", "Cancer", "Heart Failure", "Interstitial Lung Disease", "Chronic Obstructive Pulmonary Disease", "End-stage Renal Disease", "End-stage Liver Disease", "Dementia" ], "interventions": [ { "name": "Clinician Implementation Strategy Stage 1: low intensity clinician training", "type": "BEHAVIORAL" }, { "name": "Clinician Implementation Strategy Stage 2: high intensity clinician training", "type": "BEHAVIORAL" }, { "name": "Low patient engagement", "type": "BEHAVIORAL" }, { "name": "High patient engagement", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2022-09-13", "completion_date": "2025-09-30", "has_results": false, "last_update_posted_date": "2024-12-27", "last_synced_at": "2026-07-23T20:26:30.422Z", "location_count": 3, "location_summary": "Palo Alto, California • West Los Angeles, California • Aurora, Colorado", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "West Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05001009" } ] }